Author of

• 25955

  +

  P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall

  • 27452

    +

    P3.01-94 - Safety and Efficacy of First-Line Pemetrexed Versus Bevacizumab-Containing Regimens in Advanced Non-Small Cell Lung Cancer (ID 12179)

    12:00 - 13:30  |  Author(s): Andriani Charpidou
    • Abstract

    Background
    

    Previous trial data have documented the efficacy of first-line bevacizumab-based regimens, including bevacizumab-pemetrexed combinations in advanced non-small cell lung cancer (NSCLC). We herein aimed to further assess the safety and efficacy of pemetrexed monotherapy versus bevacizumab-containing or other chemotherapy regimens in a real-world NSCLC population.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    The medical records of 753 patients with advanced-stage non-squamous NSCLC, treated with bevacizumab-based regimens, pemetrexed monotherapy, or other treatments, as first-line therapy, were retrospectively reviewed and analyzed for efficacy and safety endpoints.

    4c3880bb027f159e801041b1021e88e8 Result
    

    The bevacizumab-based group had the highest percentage of partial response/PR (32.3% vs 22.8% for pemetrexed and 20.0% for other treatments) and a significantly lower incidence of progressive disease/PD (35.92%, 30.17%, and 50.48%, for pemetrexed, bevacizumab-based, and other, respectively; p < 0.0001). Bevacizumab-based regimens achieved a better overall survival (OS) rate (measured at the end of treatment) (pemetrexed 29.6%, bevacizumab-based 35.7%, and other treatments 8.9%; p < 0.0001). However, median OS was not improved (10 months, 12 months, and 13 months for pemetrexed, bevacizumab-based, and other treatments, respectively; p=0.007). A significantly higher incidence of cough (p = 0.001) and hemoptysis (p < 0.0001) in the bevacizumab-based arm, pain in the pemetrexed arm (p = 0.007), and alopecia in the other treatments arm (p < 0.0001) was observed during treatment. A significantly higher incidence of hemoptysis in the bevacizumab-based arm (p < 0.0001) and alopecia in the other treatments arm (p < 0.0001) was seen at the end of first-line treatment.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Bevacizumab-based regimens resulted in improved treatment response and short-term survival rate, but not in improved OS. An increased, albeit acceptable, toxicity was also observed among bevacizumab-treated patients as compared to those treated with pemetrexed monotherapy.

    6f8b794f3246b0c1e1780bb4d4d5dc53